开云app官网登录入口网页版-官方正版

[GetPortalCommentsPageByObjectIdResponse(id=1067768, encodeId=8d4f106e76855, content=我已经五个月了，一直是under review，正常吗，在线等，要等哭了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43585514003, createdName=ms4000001135259825, createdTime=Sun Nov 07 11:20:36 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1178938, encodeId=cc1f11e8938b8, content=投稿2个半月了，状态还是V1（Academic Editor Invited），难道杂志还没找到审稿人吗？这种情况正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201115/937b8f20c0774529b47007cd6100793f/bded1fa23ee5467e9d40e08b043a7890.jpg, createdBy=24402559221, createdName=大道至简111, createdTime=Thu Dec 30 18:39:57 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163606, encodeId=320f216360695, content=偏重的研究方向：糖尿病;临床 经验分享：15天还在AE invited...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf08742257, createdName=ms1000001042631374, createdTime=Wed Oct 18 20:24:25 CST 2023, time=2023-10-18, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2196503, encodeId=b8d521965034f, content=被Clinical endocrinology 推荐转投，我同意了，，请问又从哪里登录查看稿件动态呢？小白求帮助，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc559038572, createdName=ms8000000748328144, createdTime=Mon Apr 01 20:42:36 CST 2024, time=2024-04-01, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2145939, encodeId=5b372145939df, content=审稿速度:3.0 经验分享：投稿3个多月，催了一次，回复说找不到审稿人，让自己推荐审稿人，也是醉了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJp0sD8Z3gbQmV24MRDY7wn75cHicnUffTMDfpXJuEV3sNaw70NtickSVHcMDAxV6UZ7ROKn78GcWwA/132, createdBy=034f2309606, createdName=我爱写歌词, createdTime=Sun Jul 02 10:20:42 CST 2023, time=2023-07-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2175813, encodeId=cfa321e5813ae, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺 经验分享：2023年6月中旬投稿，10月初一审给大修，11月下旬返修后显示under review，两周后变成pending approval，到目前持续了16天了没有改变，不知道能不能接收~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/5aea3dc4251f1ef471c5d5f5a2e6ca51/40d445eef080ed392185b807ff427f40.jpg, createdBy=a8932225910, createdName=12112347m62(暂无昵称), createdTime=Tue Dec 19 14:25:06 CST 2023, time=2023-12-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1185640, encodeId=6e08118564089, content=被Clinical endocrinology 推荐转投，要不要接受。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=675c2195011, createdName=120a0830m36暂无昵称, createdTime=Tue Jan 18 15:33:16 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138051, encodeId=847b2138051ba, content=偏重的研究方向：甲状腺 经验分享：投稿9天，还没有指派学术编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5fd51628848, createdName=cq2019, createdTime=Sat May 20 19:04:50 CST 2023, time=2023-05-20, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2151959, encodeId=3e0821519598a, content=20多天一直是pending approval，大概需要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLialg5UCybAynKPP9tvWhTj2404jIJgEN2uu4oQLlXDiaRwI904aiaUahh3Cwtndog3oJfFXVicsTEPg/132, createdBy=6edb2240528, createdName=Peter忘记我, createdTime=Wed Aug 09 16:07:26 CST 2023, time=2023-08-09, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2095526, encodeId=762220955269d, content=审了三个月，两个审稿人，意见都比较友好，也好改，给了大修，刚刚提交上去，希望老天保佑接收吧，今年一篇也没接收，太衰了，求转运！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/19/eccf35eff026d776b97c650c7e9da159.jpg, createdBy=4ba62196925, createdName=120a6ac7m01(暂无昵称), createdTime=Sun Oct 23 14:27:40 CST 2022, time=2022-10-23, status=1, ipAttribution=)]

2021-11-07 ms4000001135259825

我已经五个月了，一直是under review，正常吗，在线等，要等哭了。

94 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=1067768, encodeId=8d4f106e76855, content=我已经五个月了，一直是under review，正常吗，在线等，要等哭了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43585514003, createdName=ms4000001135259825, createdTime=Sun Nov 07 11:20:36 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1178938, encodeId=cc1f11e8938b8, content=投稿2个半月了，状态还是V1（Academic Editor Invited），难道杂志还没找到审稿人吗？这种情况正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201115/937b8f20c0774529b47007cd6100793f/bded1fa23ee5467e9d40e08b043a7890.jpg, createdBy=24402559221, createdName=大道至简111, createdTime=Thu Dec 30 18:39:57 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163606, encodeId=320f216360695, content=偏重的研究方向：糖尿病;临床 经验分享：15天还在AE invited...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf08742257, createdName=ms1000001042631374, createdTime=Wed Oct 18 20:24:25 CST 2023, time=2023-10-18, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2196503, encodeId=b8d521965034f, content=被Clinical endocrinology 推荐转投，我同意了，，请问又从哪里登录查看稿件动态呢？小白求帮助，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc559038572, createdName=ms8000000748328144, createdTime=Mon Apr 01 20:42:36 CST 2024, time=2024-04-01, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2145939, encodeId=5b372145939df, content=审稿速度:3.0 经验分享：投稿3个多月，催了一次，回复说找不到审稿人，让自己推荐审稿人，也是醉了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJp0sD8Z3gbQmV24MRDY7wn75cHicnUffTMDfpXJuEV3sNaw70NtickSVHcMDAxV6UZ7ROKn78GcWwA/132, createdBy=034f2309606, createdName=我爱写歌词, createdTime=Sun Jul 02 10:20:42 CST 2023, time=2023-07-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2175813, encodeId=cfa321e5813ae, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺 经验分享：2023年6月中旬投稿，10月初一审给大修，11月下旬返修后显示under review，两周后变成pending approval，到目前持续了16天了没有改变，不知道能不能接收~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/5aea3dc4251f1ef471c5d5f5a2e6ca51/40d445eef080ed392185b807ff427f40.jpg, createdBy=a8932225910, createdName=12112347m62(暂无昵称), createdTime=Tue Dec 19 14:25:06 CST 2023, time=2023-12-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1185640, encodeId=6e08118564089, content=被Clinical endocrinology 推荐转投，要不要接受。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=675c2195011, createdName=120a0830m36暂无昵称, createdTime=Tue Jan 18 15:33:16 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138051, encodeId=847b2138051ba, content=偏重的研究方向：甲状腺 经验分享：投稿9天，还没有指派学术编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5fd51628848, createdName=cq2019, createdTime=Sat May 20 19:04:50 CST 2023, time=2023-05-20, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2151959, encodeId=3e0821519598a, content=20多天一直是pending approval，大概需要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLialg5UCybAynKPP9tvWhTj2404jIJgEN2uu4oQLlXDiaRwI904aiaUahh3Cwtndog3oJfFXVicsTEPg/132, createdBy=6edb2240528, createdName=Peter忘记我, createdTime=Wed Aug 09 16:07:26 CST 2023, time=2023-08-09, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2095526, encodeId=762220955269d, content=审了三个月，两个审稿人，意见都比较友好，也好改，给了大修，刚刚提交上去，希望老天保佑接收吧，今年一篇也没接收，太衰了，求转运！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/19/eccf35eff026d776b97c650c7e9da159.jpg, createdBy=4ba62196925, createdName=120a6ac7m01(暂无昵称), createdTime=Sun Oct 23 14:27:40 CST 2022, time=2022-10-23, status=1, ipAttribution=)]

2021-12-30 大道至简111

投稿2个半月了，状态还是V1（Academic Editor Invited），难道杂志还没找到审稿人吗？这种情况正常吗？

104 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=1067768, encodeId=8d4f106e76855, content=我已经五个月了，一直是under review，正常吗，在线等，要等哭了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43585514003, createdName=ms4000001135259825, createdTime=Sun Nov 07 11:20:36 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1178938, encodeId=cc1f11e8938b8, content=投稿2个半月了，状态还是V1（Academic Editor Invited），难道杂志还没找到审稿人吗？这种情况正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201115/937b8f20c0774529b47007cd6100793f/bded1fa23ee5467e9d40e08b043a7890.jpg, createdBy=24402559221, createdName=大道至简111, createdTime=Thu Dec 30 18:39:57 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163606, encodeId=320f216360695, content=偏重的研究方向：糖尿病;临床 经验分享：15天还在AE invited...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf08742257, createdName=ms1000001042631374, createdTime=Wed Oct 18 20:24:25 CST 2023, time=2023-10-18, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2196503, encodeId=b8d521965034f, content=被Clinical endocrinology 推荐转投，我同意了，，请问又从哪里登录查看稿件动态呢？小白求帮助，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc559038572, createdName=ms8000000748328144, createdTime=Mon Apr 01 20:42:36 CST 2024, time=2024-04-01, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2145939, encodeId=5b372145939df, content=审稿速度:3.0 经验分享：投稿3个多月，催了一次，回复说找不到审稿人，让自己推荐审稿人，也是醉了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJp0sD8Z3gbQmV24MRDY7wn75cHicnUffTMDfpXJuEV3sNaw70NtickSVHcMDAxV6UZ7ROKn78GcWwA/132, createdBy=034f2309606, createdName=我爱写歌词, createdTime=Sun Jul 02 10:20:42 CST 2023, time=2023-07-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2175813, encodeId=cfa321e5813ae, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺 经验分享：2023年6月中旬投稿，10月初一审给大修，11月下旬返修后显示under review，两周后变成pending approval，到目前持续了16天了没有改变，不知道能不能接收~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/5aea3dc4251f1ef471c5d5f5a2e6ca51/40d445eef080ed392185b807ff427f40.jpg, createdBy=a8932225910, createdName=12112347m62(暂无昵称), createdTime=Tue Dec 19 14:25:06 CST 2023, time=2023-12-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1185640, encodeId=6e08118564089, content=被Clinical endocrinology 推荐转投，要不要接受。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=675c2195011, createdName=120a0830m36暂无昵称, createdTime=Tue Jan 18 15:33:16 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138051, encodeId=847b2138051ba, content=偏重的研究方向：甲状腺 经验分享：投稿9天，还没有指派学术编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5fd51628848, createdName=cq2019, createdTime=Sat May 20 19:04:50 CST 2023, time=2023-05-20, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2151959, encodeId=3e0821519598a, content=20多天一直是pending approval，大概需要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLialg5UCybAynKPP9tvWhTj2404jIJgEN2uu4oQLlXDiaRwI904aiaUahh3Cwtndog3oJfFXVicsTEPg/132, createdBy=6edb2240528, createdName=Peter忘记我, createdTime=Wed Aug 09 16:07:26 CST 2023, time=2023-08-09, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2095526, encodeId=762220955269d, content=审了三个月，两个审稿人，意见都比较友好，也好改，给了大修，刚刚提交上去，希望老天保佑接收吧，今年一篇也没接收，太衰了，求转运！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/19/eccf35eff026d776b97c650c7e9da159.jpg, createdBy=4ba62196925, createdName=120a6ac7m01(暂无昵称), createdTime=Sun Oct 23 14:27:40 CST 2022, time=2022-10-23, status=1, ipAttribution=)]

2023-10-18 ms1000001042631374 来自江西省

偏重的研究方向：糖尿病;临床
经验分享：15天还在AE invited....

83 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1067768, encodeId=8d4f106e76855, content=我已经五个月了，一直是under review，正常吗，在线等，要等哭了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43585514003, createdName=ms4000001135259825, createdTime=Sun Nov 07 11:20:36 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1178938, encodeId=cc1f11e8938b8, content=投稿2个半月了，状态还是V1（Academic Editor Invited），难道杂志还没找到审稿人吗？这种情况正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201115/937b8f20c0774529b47007cd6100793f/bded1fa23ee5467e9d40e08b043a7890.jpg, createdBy=24402559221, createdName=大道至简111, createdTime=Thu Dec 30 18:39:57 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163606, encodeId=320f216360695, content=偏重的研究方向：糖尿病;临床 经验分享：15天还在AE invited...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf08742257, createdName=ms1000001042631374, createdTime=Wed Oct 18 20:24:25 CST 2023, time=2023-10-18, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2196503, encodeId=b8d521965034f, content=被Clinical endocrinology 推荐转投，我同意了，，请问又从哪里登录查看稿件动态呢？小白求帮助，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc559038572, createdName=ms8000000748328144, createdTime=Mon Apr 01 20:42:36 CST 2024, time=2024-04-01, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2145939, encodeId=5b372145939df, content=审稿速度:3.0 经验分享：投稿3个多月，催了一次，回复说找不到审稿人，让自己推荐审稿人，也是醉了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJp0sD8Z3gbQmV24MRDY7wn75cHicnUffTMDfpXJuEV3sNaw70NtickSVHcMDAxV6UZ7ROKn78GcWwA/132, createdBy=034f2309606, createdName=我爱写歌词, createdTime=Sun Jul 02 10:20:42 CST 2023, time=2023-07-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2175813, encodeId=cfa321e5813ae, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺 经验分享：2023年6月中旬投稿，10月初一审给大修，11月下旬返修后显示under review，两周后变成pending approval，到目前持续了16天了没有改变，不知道能不能接收~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/5aea3dc4251f1ef471c5d5f5a2e6ca51/40d445eef080ed392185b807ff427f40.jpg, createdBy=a8932225910, createdName=12112347m62(暂无昵称), createdTime=Tue Dec 19 14:25:06 CST 2023, time=2023-12-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1185640, encodeId=6e08118564089, content=被Clinical endocrinology 推荐转投，要不要接受。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=675c2195011, createdName=120a0830m36暂无昵称, createdTime=Tue Jan 18 15:33:16 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138051, encodeId=847b2138051ba, content=偏重的研究方向：甲状腺 经验分享：投稿9天，还没有指派学术编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5fd51628848, createdName=cq2019, createdTime=Sat May 20 19:04:50 CST 2023, time=2023-05-20, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2151959, encodeId=3e0821519598a, content=20多天一直是pending approval，大概需要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLialg5UCybAynKPP9tvWhTj2404jIJgEN2uu4oQLlXDiaRwI904aiaUahh3Cwtndog3oJfFXVicsTEPg/132, createdBy=6edb2240528, createdName=Peter忘记我, createdTime=Wed Aug 09 16:07:26 CST 2023, time=2023-08-09, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2095526, encodeId=762220955269d, content=审了三个月，两个审稿人，意见都比较友好，也好改，给了大修，刚刚提交上去，希望老天保佑接收吧，今年一篇也没接收，太衰了，求转运！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/19/eccf35eff026d776b97c650c7e9da159.jpg, createdBy=4ba62196925, createdName=120a6ac7m01(暂无昵称), createdTime=Sun Oct 23 14:27:40 CST 2022, time=2022-10-23, status=1, ipAttribution=)]

2024-04-01 ms8000000748328144 来自云南省

被Clinical endocrinology 推荐转投，我同意了，，请问又从哪里登录查看稿件动态呢？小白求帮助，，，

52 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1067768, encodeId=8d4f106e76855, content=我已经五个月了，一直是under review，正常吗，在线等，要等哭了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43585514003, createdName=ms4000001135259825, createdTime=Sun Nov 07 11:20:36 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1178938, encodeId=cc1f11e8938b8, content=投稿2个半月了，状态还是V1（Academic Editor Invited），难道杂志还没找到审稿人吗？这种情况正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201115/937b8f20c0774529b47007cd6100793f/bded1fa23ee5467e9d40e08b043a7890.jpg, createdBy=24402559221, createdName=大道至简111, createdTime=Thu Dec 30 18:39:57 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163606, encodeId=320f216360695, content=偏重的研究方向：糖尿病;临床 经验分享：15天还在AE invited...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf08742257, createdName=ms1000001042631374, createdTime=Wed Oct 18 20:24:25 CST 2023, time=2023-10-18, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2196503, encodeId=b8d521965034f, content=被Clinical endocrinology 推荐转投，我同意了，，请问又从哪里登录查看稿件动态呢？小白求帮助，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc559038572, createdName=ms8000000748328144, createdTime=Mon Apr 01 20:42:36 CST 2024, time=2024-04-01, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2145939, encodeId=5b372145939df, content=审稿速度:3.0 经验分享：投稿3个多月，催了一次，回复说找不到审稿人，让自己推荐审稿人，也是醉了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJp0sD8Z3gbQmV24MRDY7wn75cHicnUffTMDfpXJuEV3sNaw70NtickSVHcMDAxV6UZ7ROKn78GcWwA/132, createdBy=034f2309606, createdName=我爱写歌词, createdTime=Sun Jul 02 10:20:42 CST 2023, time=2023-07-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2175813, encodeId=cfa321e5813ae, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺 经验分享：2023年6月中旬投稿，10月初一审给大修，11月下旬返修后显示under review，两周后变成pending approval，到目前持续了16天了没有改变，不知道能不能接收~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/5aea3dc4251f1ef471c5d5f5a2e6ca51/40d445eef080ed392185b807ff427f40.jpg, createdBy=a8932225910, createdName=12112347m62(暂无昵称), createdTime=Tue Dec 19 14:25:06 CST 2023, time=2023-12-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1185640, encodeId=6e08118564089, content=被Clinical endocrinology 推荐转投，要不要接受。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=675c2195011, createdName=120a0830m36暂无昵称, createdTime=Tue Jan 18 15:33:16 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138051, encodeId=847b2138051ba, content=偏重的研究方向：甲状腺 经验分享：投稿9天，还没有指派学术编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5fd51628848, createdName=cq2019, createdTime=Sat May 20 19:04:50 CST 2023, time=2023-05-20, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2151959, encodeId=3e0821519598a, content=20多天一直是pending approval，大概需要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLialg5UCybAynKPP9tvWhTj2404jIJgEN2uu4oQLlXDiaRwI904aiaUahh3Cwtndog3oJfFXVicsTEPg/132, createdBy=6edb2240528, createdName=Peter忘记我, createdTime=Wed Aug 09 16:07:26 CST 2023, time=2023-08-09, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2095526, encodeId=762220955269d, content=审了三个月，两个审稿人，意见都比较友好，也好改，给了大修，刚刚提交上去，希望老天保佑接收吧，今年一篇也没接收，太衰了，求转运！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/19/eccf35eff026d776b97c650c7e9da159.jpg, createdBy=4ba62196925, createdName=120a6ac7m01(暂无昵称), createdTime=Sun Oct 23 14:27:40 CST 2022, time=2022-10-23, status=1, ipAttribution=)]

2023-07-02 我爱写歌词来自山东省

审稿速度:3.0
经验分享：投稿3个多月，催了一次，回复说找不到审稿人，让自己推荐审稿人，也是醉了。

80 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=1067768, encodeId=8d4f106e76855, content=我已经五个月了，一直是under review，正常吗，在线等，要等哭了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43585514003, createdName=ms4000001135259825, createdTime=Sun Nov 07 11:20:36 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1178938, encodeId=cc1f11e8938b8, content=投稿2个半月了，状态还是V1（Academic Editor Invited），难道杂志还没找到审稿人吗？这种情况正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201115/937b8f20c0774529b47007cd6100793f/bded1fa23ee5467e9d40e08b043a7890.jpg, createdBy=24402559221, createdName=大道至简111, createdTime=Thu Dec 30 18:39:57 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163606, encodeId=320f216360695, content=偏重的研究方向：糖尿病;临床 经验分享：15天还在AE invited...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf08742257, createdName=ms1000001042631374, createdTime=Wed Oct 18 20:24:25 CST 2023, time=2023-10-18, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2196503, encodeId=b8d521965034f, content=被Clinical endocrinology 推荐转投，我同意了，，请问又从哪里登录查看稿件动态呢？小白求帮助，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc559038572, createdName=ms8000000748328144, createdTime=Mon Apr 01 20:42:36 CST 2024, time=2024-04-01, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2145939, encodeId=5b372145939df, content=审稿速度:3.0 经验分享：投稿3个多月，催了一次，回复说找不到审稿人，让自己推荐审稿人，也是醉了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJp0sD8Z3gbQmV24MRDY7wn75cHicnUffTMDfpXJuEV3sNaw70NtickSVHcMDAxV6UZ7ROKn78GcWwA/132, createdBy=034f2309606, createdName=我爱写歌词, createdTime=Sun Jul 02 10:20:42 CST 2023, time=2023-07-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2175813, encodeId=cfa321e5813ae, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺 经验分享：2023年6月中旬投稿，10月初一审给大修，11月下旬返修后显示under review，两周后变成pending approval，到目前持续了16天了没有改变，不知道能不能接收~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/5aea3dc4251f1ef471c5d5f5a2e6ca51/40d445eef080ed392185b807ff427f40.jpg, createdBy=a8932225910, createdName=12112347m62(暂无昵称), createdTime=Tue Dec 19 14:25:06 CST 2023, time=2023-12-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1185640, encodeId=6e08118564089, content=被Clinical endocrinology 推荐转投，要不要接受。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=675c2195011, createdName=120a0830m36暂无昵称, createdTime=Tue Jan 18 15:33:16 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138051, encodeId=847b2138051ba, content=偏重的研究方向：甲状腺 经验分享：投稿9天，还没有指派学术编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5fd51628848, createdName=cq2019, createdTime=Sat May 20 19:04:50 CST 2023, time=2023-05-20, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2151959, encodeId=3e0821519598a, content=20多天一直是pending approval，大概需要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLialg5UCybAynKPP9tvWhTj2404jIJgEN2uu4oQLlXDiaRwI904aiaUahh3Cwtndog3oJfFXVicsTEPg/132, createdBy=6edb2240528, createdName=Peter忘记我, createdTime=Wed Aug 09 16:07:26 CST 2023, time=2023-08-09, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2095526, encodeId=762220955269d, content=审了三个月，两个审稿人，意见都比较友好，也好改，给了大修，刚刚提交上去，希望老天保佑接收吧，今年一篇也没接收，太衰了，求转运！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/19/eccf35eff026d776b97c650c7e9da159.jpg, createdBy=4ba62196925, createdName=120a6ac7m01(暂无昵称), createdTime=Sun Oct 23 14:27:40 CST 2022, time=2022-10-23, status=1, ipAttribution=)]

2023-12-19 12112347m62(暂无昵称) 来自浙江省

审稿速度:6.0 | 投稿命中率:50.0
偏重的研究方向：甲状腺
经验分享：2023年6月中旬投稿，10月初一审给大修，11月下旬返修后显示under review，两周后变成pending approval，到目前持续了16天了没有改变，不知道能不能接收~

69 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1067768, encodeId=8d4f106e76855, content=我已经五个月了，一直是under review，正常吗，在线等，要等哭了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43585514003, createdName=ms4000001135259825, createdTime=Sun Nov 07 11:20:36 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1178938, encodeId=cc1f11e8938b8, content=投稿2个半月了，状态还是V1（Academic Editor Invited），难道杂志还没找到审稿人吗？这种情况正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201115/937b8f20c0774529b47007cd6100793f/bded1fa23ee5467e9d40e08b043a7890.jpg, createdBy=24402559221, createdName=大道至简111, createdTime=Thu Dec 30 18:39:57 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163606, encodeId=320f216360695, content=偏重的研究方向：糖尿病;临床 经验分享：15天还在AE invited...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf08742257, createdName=ms1000001042631374, createdTime=Wed Oct 18 20:24:25 CST 2023, time=2023-10-18, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2196503, encodeId=b8d521965034f, content=被Clinical endocrinology 推荐转投，我同意了，，请问又从哪里登录查看稿件动态呢？小白求帮助，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc559038572, createdName=ms8000000748328144, createdTime=Mon Apr 01 20:42:36 CST 2024, time=2024-04-01, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2145939, encodeId=5b372145939df, content=审稿速度:3.0 经验分享：投稿3个多月，催了一次，回复说找不到审稿人，让自己推荐审稿人，也是醉了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJp0sD8Z3gbQmV24MRDY7wn75cHicnUffTMDfpXJuEV3sNaw70NtickSVHcMDAxV6UZ7ROKn78GcWwA/132, createdBy=034f2309606, createdName=我爱写歌词, createdTime=Sun Jul 02 10:20:42 CST 2023, time=2023-07-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2175813, encodeId=cfa321e5813ae, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺 经验分享：2023年6月中旬投稿，10月初一审给大修，11月下旬返修后显示under review，两周后变成pending approval，到目前持续了16天了没有改变，不知道能不能接收~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/5aea3dc4251f1ef471c5d5f5a2e6ca51/40d445eef080ed392185b807ff427f40.jpg, createdBy=a8932225910, createdName=12112347m62(暂无昵称), createdTime=Tue Dec 19 14:25:06 CST 2023, time=2023-12-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1185640, encodeId=6e08118564089, content=被Clinical endocrinology 推荐转投，要不要接受。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=675c2195011, createdName=120a0830m36暂无昵称, createdTime=Tue Jan 18 15:33:16 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138051, encodeId=847b2138051ba, content=偏重的研究方向：甲状腺 经验分享：投稿9天，还没有指派学术编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5fd51628848, createdName=cq2019, createdTime=Sat May 20 19:04:50 CST 2023, time=2023-05-20, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2151959, encodeId=3e0821519598a, content=20多天一直是pending approval，大概需要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLialg5UCybAynKPP9tvWhTj2404jIJgEN2uu4oQLlXDiaRwI904aiaUahh3Cwtndog3oJfFXVicsTEPg/132, createdBy=6edb2240528, createdName=Peter忘记我, createdTime=Wed Aug 09 16:07:26 CST 2023, time=2023-08-09, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2095526, encodeId=762220955269d, content=审了三个月，两个审稿人，意见都比较友好，也好改，给了大修，刚刚提交上去，希望老天保佑接收吧，今年一篇也没接收，太衰了，求转运！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/19/eccf35eff026d776b97c650c7e9da159.jpg, createdBy=4ba62196925, createdName=120a6ac7m01(暂无昵称), createdTime=Sun Oct 23 14:27:40 CST 2022, time=2022-10-23, status=1, ipAttribution=)]

2022-01-18 120a0830m36暂无昵称

被Clinical endocrinology 推荐转投，要不要接受。。。

94 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=1067768, encodeId=8d4f106e76855, content=我已经五个月了，一直是under review，正常吗，在线等，要等哭了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43585514003, createdName=ms4000001135259825, createdTime=Sun Nov 07 11:20:36 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1178938, encodeId=cc1f11e8938b8, content=投稿2个半月了，状态还是V1（Academic Editor Invited），难道杂志还没找到审稿人吗？这种情况正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201115/937b8f20c0774529b47007cd6100793f/bded1fa23ee5467e9d40e08b043a7890.jpg, createdBy=24402559221, createdName=大道至简111, createdTime=Thu Dec 30 18:39:57 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163606, encodeId=320f216360695, content=偏重的研究方向：糖尿病;临床 经验分享：15天还在AE invited...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf08742257, createdName=ms1000001042631374, createdTime=Wed Oct 18 20:24:25 CST 2023, time=2023-10-18, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2196503, encodeId=b8d521965034f, content=被Clinical endocrinology 推荐转投，我同意了，，请问又从哪里登录查看稿件动态呢？小白求帮助，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc559038572, createdName=ms8000000748328144, createdTime=Mon Apr 01 20:42:36 CST 2024, time=2024-04-01, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2145939, encodeId=5b372145939df, content=审稿速度:3.0 经验分享：投稿3个多月，催了一次，回复说找不到审稿人，让自己推荐审稿人，也是醉了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJp0sD8Z3gbQmV24MRDY7wn75cHicnUffTMDfpXJuEV3sNaw70NtickSVHcMDAxV6UZ7ROKn78GcWwA/132, createdBy=034f2309606, createdName=我爱写歌词, createdTime=Sun Jul 02 10:20:42 CST 2023, time=2023-07-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2175813, encodeId=cfa321e5813ae, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺 经验分享：2023年6月中旬投稿，10月初一审给大修，11月下旬返修后显示under review，两周后变成pending approval，到目前持续了16天了没有改变，不知道能不能接收~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/5aea3dc4251f1ef471c5d5f5a2e6ca51/40d445eef080ed392185b807ff427f40.jpg, createdBy=a8932225910, createdName=12112347m62(暂无昵称), createdTime=Tue Dec 19 14:25:06 CST 2023, time=2023-12-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1185640, encodeId=6e08118564089, content=被Clinical endocrinology 推荐转投，要不要接受。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=675c2195011, createdName=120a0830m36暂无昵称, createdTime=Tue Jan 18 15:33:16 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138051, encodeId=847b2138051ba, content=偏重的研究方向：甲状腺 经验分享：投稿9天，还没有指派学术编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5fd51628848, createdName=cq2019, createdTime=Sat May 20 19:04:50 CST 2023, time=2023-05-20, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2151959, encodeId=3e0821519598a, content=20多天一直是pending approval，大概需要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLialg5UCybAynKPP9tvWhTj2404jIJgEN2uu4oQLlXDiaRwI904aiaUahh3Cwtndog3oJfFXVicsTEPg/132, createdBy=6edb2240528, createdName=Peter忘记我, createdTime=Wed Aug 09 16:07:26 CST 2023, time=2023-08-09, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2095526, encodeId=762220955269d, content=审了三个月，两个审稿人，意见都比较友好，也好改，给了大修，刚刚提交上去，希望老天保佑接收吧，今年一篇也没接收，太衰了，求转运！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/19/eccf35eff026d776b97c650c7e9da159.jpg, createdBy=4ba62196925, createdName=120a6ac7m01(暂无昵称), createdTime=Sun Oct 23 14:27:40 CST 2022, time=2022-10-23, status=1, ipAttribution=)]

2023-05-20 cq2019 来自湖北省

偏重的研究方向：甲状腺
经验分享：投稿9天，还没有指派学术编辑

84 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=1067768, encodeId=8d4f106e76855, content=我已经五个月了，一直是under review，正常吗，在线等，要等哭了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43585514003, createdName=ms4000001135259825, createdTime=Sun Nov 07 11:20:36 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1178938, encodeId=cc1f11e8938b8, content=投稿2个半月了，状态还是V1（Academic Editor Invited），难道杂志还没找到审稿人吗？这种情况正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201115/937b8f20c0774529b47007cd6100793f/bded1fa23ee5467e9d40e08b043a7890.jpg, createdBy=24402559221, createdName=大道至简111, createdTime=Thu Dec 30 18:39:57 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163606, encodeId=320f216360695, content=偏重的研究方向：糖尿病;临床 经验分享：15天还在AE invited...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf08742257, createdName=ms1000001042631374, createdTime=Wed Oct 18 20:24:25 CST 2023, time=2023-10-18, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2196503, encodeId=b8d521965034f, content=被Clinical endocrinology 推荐转投，我同意了，，请问又从哪里登录查看稿件动态呢？小白求帮助，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc559038572, createdName=ms8000000748328144, createdTime=Mon Apr 01 20:42:36 CST 2024, time=2024-04-01, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2145939, encodeId=5b372145939df, content=审稿速度:3.0 经验分享：投稿3个多月，催了一次，回复说找不到审稿人，让自己推荐审稿人，也是醉了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJp0sD8Z3gbQmV24MRDY7wn75cHicnUffTMDfpXJuEV3sNaw70NtickSVHcMDAxV6UZ7ROKn78GcWwA/132, createdBy=034f2309606, createdName=我爱写歌词, createdTime=Sun Jul 02 10:20:42 CST 2023, time=2023-07-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2175813, encodeId=cfa321e5813ae, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺 经验分享：2023年6月中旬投稿，10月初一审给大修，11月下旬返修后显示under review，两周后变成pending approval，到目前持续了16天了没有改变，不知道能不能接收~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/5aea3dc4251f1ef471c5d5f5a2e6ca51/40d445eef080ed392185b807ff427f40.jpg, createdBy=a8932225910, createdName=12112347m62(暂无昵称), createdTime=Tue Dec 19 14:25:06 CST 2023, time=2023-12-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1185640, encodeId=6e08118564089, content=被Clinical endocrinology 推荐转投，要不要接受。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=675c2195011, createdName=120a0830m36暂无昵称, createdTime=Tue Jan 18 15:33:16 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138051, encodeId=847b2138051ba, content=偏重的研究方向：甲状腺 经验分享：投稿9天，还没有指派学术编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5fd51628848, createdName=cq2019, createdTime=Sat May 20 19:04:50 CST 2023, time=2023-05-20, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2151959, encodeId=3e0821519598a, content=20多天一直是pending approval，大概需要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLialg5UCybAynKPP9tvWhTj2404jIJgEN2uu4oQLlXDiaRwI904aiaUahh3Cwtndog3oJfFXVicsTEPg/132, createdBy=6edb2240528, createdName=Peter忘记我, createdTime=Wed Aug 09 16:07:26 CST 2023, time=2023-08-09, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2095526, encodeId=762220955269d, content=审了三个月，两个审稿人，意见都比较友好，也好改，给了大修，刚刚提交上去，希望老天保佑接收吧，今年一篇也没接收，太衰了，求转运！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/19/eccf35eff026d776b97c650c7e9da159.jpg, createdBy=4ba62196925, createdName=120a6ac7m01(暂无昵称), createdTime=Sun Oct 23 14:27:40 CST 2022, time=2022-10-23, status=1, ipAttribution=)]

2023-08-09 Peter忘记我来自河北省

20多天一直是pending approval，大概需要等多久

99 0

[GetPortalCommentsPageByObjectIdResponse(id=1067768, encodeId=8d4f106e76855, content=我已经五个月了，一直是under review，正常吗，在线等，要等哭了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43585514003, createdName=ms4000001135259825, createdTime=Sun Nov 07 11:20:36 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1178938, encodeId=cc1f11e8938b8, content=投稿2个半月了，状态还是V1（Academic Editor Invited），难道杂志还没找到审稿人吗？这种情况正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201115/937b8f20c0774529b47007cd6100793f/bded1fa23ee5467e9d40e08b043a7890.jpg, createdBy=24402559221, createdName=大道至简111, createdTime=Thu Dec 30 18:39:57 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163606, encodeId=320f216360695, content=偏重的研究方向：糖尿病;临床 经验分享：15天还在AE invited...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf08742257, createdName=ms1000001042631374, createdTime=Wed Oct 18 20:24:25 CST 2023, time=2023-10-18, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2196503, encodeId=b8d521965034f, content=被Clinical endocrinology 推荐转投，我同意了，，请问又从哪里登录查看稿件动态呢？小白求帮助，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc559038572, createdName=ms8000000748328144, createdTime=Mon Apr 01 20:42:36 CST 2024, time=2024-04-01, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2145939, encodeId=5b372145939df, content=审稿速度:3.0 经验分享：投稿3个多月，催了一次，回复说找不到审稿人，让自己推荐审稿人，也是醉了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJp0sD8Z3gbQmV24MRDY7wn75cHicnUffTMDfpXJuEV3sNaw70NtickSVHcMDAxV6UZ7ROKn78GcWwA/132, createdBy=034f2309606, createdName=我爱写歌词, createdTime=Sun Jul 02 10:20:42 CST 2023, time=2023-07-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2175813, encodeId=cfa321e5813ae, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺 经验分享：2023年6月中旬投稿，10月初一审给大修，11月下旬返修后显示under review，两周后变成pending approval，到目前持续了16天了没有改变，不知道能不能接收~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/5aea3dc4251f1ef471c5d5f5a2e6ca51/40d445eef080ed392185b807ff427f40.jpg, createdBy=a8932225910, createdName=12112347m62(暂无昵称), createdTime=Tue Dec 19 14:25:06 CST 2023, time=2023-12-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1185640, encodeId=6e08118564089, content=被Clinical endocrinology 推荐转投，要不要接受。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=675c2195011, createdName=120a0830m36暂无昵称, createdTime=Tue Jan 18 15:33:16 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138051, encodeId=847b2138051ba, content=偏重的研究方向：甲状腺 经验分享：投稿9天，还没有指派学术编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5fd51628848, createdName=cq2019, createdTime=Sat May 20 19:04:50 CST 2023, time=2023-05-20, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2151959, encodeId=3e0821519598a, content=20多天一直是pending approval，大概需要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLialg5UCybAynKPP9tvWhTj2404jIJgEN2uu4oQLlXDiaRwI904aiaUahh3Cwtndog3oJfFXVicsTEPg/132, createdBy=6edb2240528, createdName=Peter忘记我, createdTime=Wed Aug 09 16:07:26 CST 2023, time=2023-08-09, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2095526, encodeId=762220955269d, content=审了三个月，两个审稿人，意见都比较友好，也好改，给了大修，刚刚提交上去，希望老天保佑接收吧，今年一篇也没接收，太衰了，求转运！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/19/eccf35eff026d776b97c650c7e9da159.jpg, createdBy=4ba62196925, createdName=120a6ac7m01(暂无昵称), createdTime=Sun Oct 23 14:27:40 CST 2022, time=2022-10-23, status=1, ipAttribution=)]

2022-10-23 120a6ac7m01(暂无昵称)

审了三个月，两个审稿人，意见都比较友好，也好改，给了大修，刚刚提交上去，希望老天保佑接收吧，今年一篇也没接收，太衰了，求转运！

105 7

展开7条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务